Logos Global Management »

Inhibrx shares owned by Logos Global Management

Quarter-by-quarter ownership of Inhibrx (INBX) shares owned by Logos Global Management from 13F filings

Historical chart of Logos Global Management investment in Inhibrx

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx by Logos Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $23M 600k 38.00
2020-09-30 $5.6M 312k 18.00

More positions owned by Logos Global Management

Cytokinetics Com New (CYTK)
Apellis Pharmaceuticals (APLS)
Sarepta Therapeutics Call Option (SRPT)
Ideaya Biosciences (IDYA)
Argenx Se Sponsored Adr (ARGX)
Olema Pharmaceuticals (OLMA)
Immunovant (IMVT)
Structure Therapeutics Sponsored Ads (GPCR)
Rocket Pharmaceuticals (RCKT)
Rayzebio
Ambrx Biopharma
Karuna Therapeutics Ord
Immunocore Hldgs Ads (IMCR)
Dyne Therapeutics (DYN)
Morphosys Sponsored Ads Call Option (MOR)

View all positions for Logos Global Management

Top funds holding Inhibrx

Viking Global Investors
RA Capital Management
Perceptive Advisors
Vanguard Group
Arrowpoint Asset Management
Bank of America Corporation
Logos Global Management
Partner Fund Management
Russell Investments
Citadel Advisors
Caption Management
Millennium Management
Charles Schwab Investment Management
Sphera Funds Management
Two Sigma Advisers

View all funds holding Inhibrx